Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Glargine in Pediatric DKA
NCT02548494Terminated
- Sponsor
- Erlanger Health System
- Start
- Nov 2015
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of insulin glargine in diabetic ketoacidosis (DKA) (2 arms), sponsored by Erlanger Health System. Primary endpoint: Blood glucose. Started Nov 2015; status: terminated.
02
Drugs
insulin glargine
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on NCT02548494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548494.